Emerging Targeted and Combination Strategies in Metastatic Pancreatic Ductal Adenocarcinoma

This forward looking segment examines how emerging targeted therapies may be integrated with chemotherapy for metastatic pancreatic ductal adenocarcinoma. Faculty discuss evolving strategies involving agents such as KRAS and PRMT5 inhibitors and how these approaches may complement existing cytotoxic regimens.

Panelists explore which patient subsets may benefit most from targeted and combination strategies, emphasizing the importance of molecular characterization and disease biology. The discussion includes whether these agents are more likely to be used alongside chemotherapy, as maintenance therapy, or in sequential treatment approaches.

Faculty also address the challenges associated with incorporating novel agents into routine practice, including toxicity management, patient selection, and optimal sequencing. Emphasis is placed on the need for well designed clinical trials that clearly define benefit and identify predictive biomarkers.

This segment underscores that while targeted therapies hold promise, their successful integration into metastatic pancreatic ductal adenocarcinoma care will depend on robust clinical evidence and thoughtful implementation strategies.